Christopher Bunick’s Post

View profile for Christopher Bunick, graphic

Associate Professor of Dermatology and Translational Biomedicine at Yale University School of Medicine

I am excited to share the publication of the #crystal #structure of #Bimekizumab Fab fragment bound to IL-17F. A collaborative effort from the Bunick lab and UCB, this article provides #dermatologists and the #medical and #scientific community a #molecular basis for how and why bimekizumab binds to and inhibits IL-17A and IL-17F. This dual inhibition has made a remarkable impact on the #treatment of plaque #psoriasis, and is poised for #FDAapproval for psoriatic #arthritis and #hidradenitis suppurativa in the coming months. Please dive into the molecular differentiation of Bimekizumab from other IL-17 targeted biologics! Another victory for molecular and structural #science, and more importantly, for the #patients who will benefit from this #therapy! https://lnkd.in/eeaeYe-V

Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F Inhibition

Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F Inhibition

sciencedirect.com

James Q. Del Rosso, DO

If you want the best, then look no further, you found it here.

4mo

Nice work, Chris.

To view or add a comment, sign in

Explore topics